Antibiotic Cycling: Is It Ready for Prime Time? | Infection Control & Hospital Epidemiology | Cambridge Core (original) (raw)

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

References

1.Sagan, D, Margulis, L. Garden of Microbial Delights: A Practical Guide to the Subvisible World. Boston, MA: Harcourt Brace Jovanovich, Inc, Publishers; 1988:74.Google Scholar

2.McGowan, JE Jr.Minimizing antimicrobial resistance in hospital bacteria: can switching or cycling drugs help? Infect Control Hosp Epidemiol 1986;7:573–576.CrossRefGoogle ScholarPubMed

3.Wise, R, Hart, T, Cars, O, Streulens, M, Helmuth, R, Huovinen, P, et al. Antimicrobial resistance. Is a major threat to public health. BMJ 1998;317:609–610.CrossRefGoogle Scholar

4.Gerberding, JL, McGowan, JE Jr, Tenover, FC. Emerging nosocomial infections and antimicrobial resistance. Curr Clin Top Infect Dis 1999;19:83–98.Google ScholarPubMed

5.Shlaes, DM, Gerding, DN, John, JF Jr, Craig, WA, Bornstein, DL, Duncan, RA, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997;18:275–291.CrossRefGoogle Scholar

6.John, JF Jr, Fishman, NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997;24:471–485.CrossRefGoogle ScholarPubMed

9.Betts, RF, Valenti, WM, Chapman, SW, Chonmaitree, T, Mowrer, G, Pincus, P, et al. Five-year surveillance of aminoglycoside usage in a university hospital. Ann Intern Med 1984;100:219–222.CrossRefGoogle ScholarPubMed

10.Gerding, DN. Antimicrobial cycling: lessons learned from the aminoglycoside experience. Infect Control Hosp Epidemiol 2000;21 (suppl):S12–S17.CrossRefGoogle ScholarPubMed

11.Gerding, DN, Larson, TA, Hughes, RA, Weiler, M, Shanholtzer, C, Peterson, LR. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother 1991;35:1284–1290.CrossRefGoogle ScholarPubMed

12.Gerding, DN, Larson, TA. Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical Center. Am J Med 1985;79:1–7.CrossRefGoogle ScholarPubMed

13.Archibald, L, Phillips, L, Monnet, D, McGowan, JE Jr, Tenover, F, Gaynes, R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997;24:211–215.CrossRefGoogle ScholarPubMed

14.Fridkin, SK, Edwards, JR, Pichette, SC, Pryor, ER, McGowan, JE Jr, Tenover, FC, et al. Determinants of vancomycin use in adult intensive care units in 41 Unites States hospitals. Clin Infect Dis 1999;28:1119–1125.CrossRefGoogle ScholarPubMed

15.Hiramatsu, K, Aritaka, N, Hanaki, H, Kawasaki, S, Hosada, Y, Hori, S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350:1670–1673.CrossRefGoogle ScholarPubMed

16.Lavin, BS. Antibiotic cycling and marketing into the 21st century: a perspective from the pharmaceutical industry. Infect Control Hosp Epidemiol 2000;21 (suppl) :S32–S35.CrossRefGoogle ScholarPubMed

17.Kollef, MH, Vlasnik, J, Sharpless, L, Pasque C, Murphy, D, Fraser, V. Scheduled change of antibiotic classes. A strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997;156(4 pt 1):1040–1048.CrossRefGoogle ScholarPubMed

18.Landman, D, Chockalingam, M, Quale, JM. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in hospital antibiotic formulary. Clin Infect Dis 1998;28:1062–1066.CrossRefGoogle Scholar

19.Bradley, SJ, Wilson, ALT, Allen, MC, Sher, HA, Goldstone, AH, Scott, GM. The control of hyperendemic glycopeptide-resistant Enterococcus spp on a haematology unit by changing antibiotic usage. J Antimicrob Chemother 1999;43:261–266.CrossRefGoogle ScholarPubMed

20.Dominguez, EA, Smith, TL, Reed, E, Sanders, CC, Sanders, WE Jr. A pilot study of antibiotic cycling in a hematology-oncology unit. Infect Control Hosp Epidemiol 2000;21(suppl):S4–S8.CrossRefGoogle Scholar

21.Hyatt, JM, Schentag, JJ. Potential role of pharmacokinetics, pharmacodynamics, and computerized databases in controlling bacterial resistance. Infect Control Hosp Epidemiol 2000;21(suppl):S18–S21.CrossRefGoogle ScholarPubMed

22.Arbeit, RD. Laboratory procedures for the epidemiologic analysis of microorganisms. In: Murray, PR, Baron, EJ, Pfaller, MA, Tenover, FC, Yolken, RH, eds. Manual of Clinical Microbiology. Washington, DC: American Society for Microbiology Press; 1999:125–137.Google Scholar

23.Bonhoeffer, S, Lipsitch, M, Levin, BR. Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci U S A 1997;94:12106–12111.CrossRefGoogle ScholarPubMed

24.McGowan, JE Jr.Strategies for study of the role of cycling on antimicrobial use and resistance. Infect Control Hosp Epidemiol 2000;21 (suppl):S36–S43.CrossRefGoogle ScholarPubMed

25.John, JF Jr, Rice, LB. The microbial genetics of antibiotic cycling. Infect Control Hosp Epidemiol 2000;21(suppl):S22–S31.CrossRefGoogle ScholarPubMed

26.Hall, RM, Collis, CM. Antibiotic resistance in gram-negative bacteria: the role of gene cassettes and integrons. Drug Resistance Updates 1999;1:109–119.CrossRefGoogle Scholar